Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — FY2022 Earnings Presentation
16 slides from Ironwood Pharmaceuticals's earnings presentation, Feb 16, 2023
Slide 1: Ironwood Q4 and FY 2022 Investor Update
Ironwood Q4 and FY 2022 Investor Update February 16, 2023 .
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision; our strategy, business, financial position and operations, including
Slide 3: Introduction
Introduction Matt Roache
Slide 4: Today's Agenda
Today’s Agenda • Introduction Matt Roache, Director, Investor Relations • Strategic Priorities and Commercial Performance Tom McCourt, Chief Executive Officer • Pipeline Update Mike Shetzline, M.D., Ph.D., Chief Medical Officer • Q4 and FY 2022 Financial Highlights & 2023 Guidance Sravan Emany, Chie
Slide 5: Strategic Priorities and Commercial Performance
Strategic Priorities and Commercial Performance Tom McCourt
Slide 6: Execution across our three strategic priorities is positioning our company for future growth
Execution across our three strategic priorities is positioning our company for future growth 2022 Highlights 2023 Outlook Maximize LINZESS +9% Y/Y EUTRx demand growth1 • FDA granted priority review to the sNDA for FC in pediatric patients Increased market leading TRx share to 45%1 ages 6-17 and
Slide 7: We continue to see strong demand for LINZESS and there is significant opportunity to reach appropriate new patients
We continue to see strong demand for LINZESS and there is significant opportunity to reach appropriate new patients Impressive Demand Large Market Opportunity Growth Since Launch LINZESS Extended Unit Growth1 Drivers of Estimated population of pediatric 4,000,000 Continued Growth: ~6M patients aged
Slide 8: Pipeline Update
Pipeline Update Mike Shetzline
Slide 9: 2023 is an exciting year for our development programs as we anticipate reaching new milestones
2023 is an exciting year for our development programs as we anticipate reaching new milestones Linaclotide Lifecycle Management Development Assets CNP-104 IW-3300 Pediatric program in FC & IBS-C Primary Biliary Interstitial Cystitis / Cholangitis (PBC) Bladder Pain Syndrome (IC/BPS) • FC affects an
Slide 10: Financial Performance and 2023 Financial Guidance
Q4 and FY 2022 Financial Performance and 2023 Financial Guidance Sravan Emany
Slide 11: FY 2022 financial performance
FY 2022 financial performance $1,002M $411M U.S. LINZESS Net Sales1 Total Ironwood Revenues Strong LINZESS prescription demand growth was offset by Primarily driven by $399M in U.S. LINZESS price and inventory channel fluctuations collaboration revenue LINZESS commercial margin: 73%1 $175M $252M GAA
Slide 12: We are maintaining our FY 2023 guidance
We are maintaining our FY 2023 guidance FY 2023 Guidance LINZESS U.S. 3% – 5% net sales growth Ironwood revenue $420 – $435 million Adjusted EBITDA1 >$250 million 1 Adjusted EBITDA is calculated by subtracting mark-to-market adjustments on derivatives related to Ironwood’s 2022 Convertible Notes, re
Slide 13: Thank You
Thank You
Slide 14: Q4 and FY 2022 Financial Summary
Q4 and FY 2022 Financial Summary Reconciliation of GAAP results to non-GAAP financial measures1 Three Months Ended Twelve Months Ended December 31, 2022 December 31, 2022 (000s, except per share (000s, except per share amounts) amounts) GAAP net income $ 48,867 $ 175,065 Adjustments: Mark-to-market
Slide 15: Q4 and FY 2022 Financial Summary
Q4 and FY 2022 Financial Summary Reconciliation of GAAP net income to adjusted EBITDA Three Months Ended Twelve Months Ended December 31, 2022 December 31, 2022 (000s) (000s) GAAP net income1 $ 48,867 $ 175,065 Adjustments: Mark-to-market adjustments on the derivatives related to 18 (182) convertibl
Slide 16: Q4 and FY 2022 Financial Summary
Q4 and FY 2022 Financial Summary LINZESS U.S. Brand Collaboration Commercial Profit & Collaboration Revenue1 Ironwood & AbbVie Total Net Profit Three Months Ended Twelve Months Ended Three Months Ended Twelve Months Ended December 31, 2022 December 31, 2022 December 31, 2022 December 31, 2022 (000s)
Ironwood Pharmaceuticals — FY2022 Earnings Presentation on 6ix